SHARED RESOURCE MANAGEMENT ? PROJECT SUMMARY/ABSTRACT The Shared Resource Management team is responsible for overseeing the operations, budgets, development, and scientific quality of the ten Cold Spring Harbor Laboratory Cancer Center Shared Resources. These Resources are instrumental for research in the Cancer Center, with 40% (163/408) of publications/preprints using Shared Resources in the last five years. In addition, the Shared Resources spur collaboration as evidenced by 15% of publications/preprints (61/408) including Shared Resource staff as co-authors in the last five years. During the current funding period, the Management team was reorganized and expanded to provide robust support for the Cancer Center Shared Resources. The Management team is now led by Nicholas Tonks (Deputy Director of Operations) with the support of Denise Roberts (Deputy Director of Administration), Sydney Gary (Associate Director of Operations and Administration), and Robert Gerdes (Core Facility Business Manager). This team works with the support of Institutional departments to provide oversight, planning, and evaluation of the services, staff, and equipment in the Resources. In addition, the Management team and Institutional partners oversee budgets and recommend allocation of funds to support the Shared Resources. The Management team also ensures that Shared Resources continue to provide outstanding research support through routine user feedback, communication, and training. As members of the Cancer Center Senior Leadership, Tonks and Roberts advise the Cancer Center Director (David Tuveson) and participate in decisions regarding the establishment of new Shared Resources or the discontinuation of services that are no longer relevant. During the current funding period, the Shared Resource management has led the development of new Single-Cell Biology and Organoid Shared Resources; managed the merger of the Next Generation Genomics and Bioinformatics Shared Resources into a new Sequencing Technologies and Analysis Shared Resource; and discontinued services for Gene Targeting and Sanger DNA sequencing. The current application outlines ongoing efforts to maintain the highest quality services at competitive rates, while exploring new technologies that will support the mission of the Cancer Center.